drugset / Trial / NCT00154700

Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer

NCT00154700

Phase 2 Completed 40 enrolled National Taiwan University Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy.

Timeline

Start
2001-01
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified
Subject Paclitaxel Small molecule
Subject fluorouracil Small molecule
Subject folic acid Other / unclassified

Indications